Theranexus SA (FR:ALTHX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theranexus, in collaboration with the Beyond Batten Disease Foundation, has announced promising phase I/II trial results for Batten-1 in treating Batten disease CLN3, showing potential in stabilizing visual acuity. These findings, presented at the Child Neurology Society Annual Meeting, support the advancement to a phase III trial, with visual acuity as the primary endpoint. The company is exploring options to fund the next trial phase, highlighting its commitment to advancing treatment for this rare disease.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.